Cargando…

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

The mechanistic target of rapamycin (mTOR) drives several physiologic and pathologic cellular processes and is frequently deregulated in different types of tumors, including glioblastoma (GBM). Despite recent advancements in understanding the molecular mechanisms involved in GBM biology, the surviva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mecca, Carmen, Giambanco, Ileana, Donato, Rosario, Arcuri, Cataldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312595/ https://www.ncbi.nlm.nih.gov/pubmed/30662577 http://dx.doi.org/10.1155/2018/9230479

Ejemplares similares

Microglia and Aging: The Role of the TREM2–DAP12 and CX3CL1-CX3CR1 Axes
por: Mecca, Carmen, et al.
Publicado: (2018)

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT
por: Mecca, Carmen, et al.
Publicado: (2018)

The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS
por: Arcuri, Cataldo, et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond
por: Sorci, Guglielmo, et al.
Publicado: (2010)

Cellular and molecular mechanisms of sarcopenia: the S100B perspective
por: Riuzzi, Francesca, et al.
Publicado: (2018)

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013)

Probing Internalization Effects and Biocompatibility of Ultrasmall Zirconium Metal-Organic Frameworks UiO-66 NP in U251 Glioblastoma Cancer Cells
por: Arcuri, Cataldo, et al.
Publicado: (2018)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme
por: Yao, Weiqi, et al.
Publicado: (2021)

Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment
por: Singh, Shilpi, et al.
Publicado: (2023)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway
por: Wang, Jiwei, et al.
Publicado: (2016)

Targeting mTOR for cancer therapy
por: Hua, Hui, et al.
Publicado: (2019)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

mTOR signaling in glioblastoma: lessons learned from bench to bedside
por: Akhavan, David, et al.
Publicado: (2010)

mTOR Modulates Intercellular Signals for Enlargement and Infiltration in Glioblastoma Multiforme
por: Ryskalin, Larisa, et al.
Publicado: (2020)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
por: Papavassiliou, Kostas A., et al.
Publicado: (2021)

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
por: Barzegar Behrooz, Amir, et al.
Publicado: (2022)

The role of mTOR pathway as target for treatment in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
por: Lyu, Jing-Wei, et al.
Publicado: (2019)

Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions
por: Yardley, Denise A.
Publicado: (2013)

Targeting mTOR dependency in pancreatic cancer
por: Morran, Douglas C, et al.
Publicado: (2014)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
por: Folgiero, Valentina, et al.
Publicado: (2016)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
por: Maiese, Kenneth
Publicado: (2015)

Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
por: Dumas, Anaelle A, et al.
Publicado: (2020)

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma
por: Benavides-Serrato, Angelica, et al.
Publicado: (2020)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hjnrb47varrmls1j5nh699ha32